Trial Profile

Multicenter Phase II Trial of Durvalumab (MEDI4736) with Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
Indications Early breast cancer
Focus Therapeutic Use
Acronyms DTP

Most Recent Events

10 Mar 2025 Planned End Date changed from 1 Feb 2025 to 1 Dec 2025.
10 Apr 2024 Status changed from recruiting to active, no longer recruiting.
10 Apr 2024 Results assessing efficacy of chemotherapy-free neoadjuvant regimen with DTP in HER2-enriched early breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com